Collaboration Agreements (Tables)

12 Months Ended

Dec. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Collaboration Revenue

Collaboration Revenue

Revenue disaggregated by collaboration agreement and performance obligation is as follows (in thousands):

	Year Ended December 31,
	2022		2021		2020
Takeda Collaboration Agreement:
Takeda Collaboration Agreement Services(1)	$	51,916	$	19,921	$	27,155
PTV:PGRN Collaboration Agreement	—		5,000		—
ATV:TREM2 Collaboration Agreement	—		5,000		—
Total Takeda Collaboration Revenue	51,916		29,921		27,155
Sanofi Collaboration Agreement:
CNS Program License	40,000		—		—
Peripheral Program License	10,000		15,000		—
Alzheimer's Disease Services(2)	3,398		4		98
Retained Activities	—		—		969
Total Sanofi Collaboration Revenue	53,398		15,004		1,067
Biogen Collaboration Agreement:
LRRK2 Program License	—		—		306,545
Option Research Services(3)	3,149		3,736		892
Total Biogen Collaboration Revenue	3,149		3,736		307,437
Total Collaboration Revenue	$	108,463	$	48,661	$	335,659

_________________________________________________

(1)$27.9 million, $15.9 million, and $19.6 million of revenue for the years ended December 31, 2022, 2021 and 2020 was included in the contract liability balance at the beginning of the year.

(2)Revenue for the years ended December 31, 2022, 2021 and 2020 represent amounts that were included in the contract liability balance at the beginning of the respective year.

(3)Revenue for the years ended December 31, 2022 and 2021 represents amounts that were included in the contract liability balance at the beginning of the year.